When was Affinivax founded?

Affinivax was founded in 2013 and raised its 1st funding round 1 year after it was founded.

Where is Affinivax located?

Affinivax is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts.

How many employees does Affinivax have?

As of Dec 31, 2022, Affinivax has 132 employees, reflecting a 70% year-over-year growth in headcount.

Is Affinivax a funded company?

Affinivax is a funded company, having raised a total of $359M across 5 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Oct 30, 2014.

How much is Affinivax worth?

The last known valuation of Affinivax was $***** as of Feb 05, 2016.

When was the latest funding round of Affinivax?

Affinivax's latest funding was a $***** Series C round on Jan 07, 2021, with participation from 13 investors. Its primary sector is Infectious Diseases. In United States, the Infectious Diseases sector has seen $252M in funding in 2026 to date.

Where does Affinivax rank among its competitors?

Affinivax ranks 9th amongst 202 active competitors, of which 60 are funded. It stands 3rd in terms of total funding among its competitors. The most recent competitor to raise funding was Centauri Therapeutics, which secured $8.1M in Feb, 2026.

Who are the top competitors of Affinivax?

Affinivax's top competitors include Insmed, Evofem and ImmunityBio. Among them, Centauri Therapeutics secured the most recent funding round in February, 2026.

Affinivax - 2026 Company Profile, Team, Funding & Competitors

Affinivax is an acquired company based in Cambridge (United States), founded in 2013 by Steven Brugger. It operates as a Developer of technology-based conjugate vaccines against infectious diseases. Affinivax has raised $359M in funding from investors like Gates Foundation, Foresite Capital and Rock Springs Capital, with last known valuation of $*****. The company has 202 active competitors, including 60 funded and 46 that have exited. Its top competitors include companies like Insmed, Evofem and ImmunityBio.

Company Details

Developer of technology-based conjugate vaccines against infectious diseases. The multiple antigen-presenting system (MAPS) vaccine platforms enable the conjugation of protective polysaccharides and proteins in a single vaccine and induce a broad and protective immune response. The company is developing its vaccine program for pathogenic microorganisms.

Website: affinivax.com
Social
Registered Address: Cambridge, Massachusetts

Key Metrics

Founded Year

2013

Location

Cambridge, United States

Stage

Acquired

Total Funding

$359M in 5 rounds

Latest Funding Round

Series C, Jan 07, 2021, $*****

Last Known Valuation

$***** as on Feb 05, 2016

Investors

Gates Foundation & 15 more

Ranked

9^th among 202 active competitors

Employee Count

132 as on Dec 31, 2022

Similar Companies

Insmed & 271 more

Exit Details

Acquired by GSK (May 31, 2022)

View Affinivax's full profile

Affinivax is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
AFFINIVAX INC CIN: 464701432 , United States, Active	Dec 26, 999	-	132 (As on Dec 31, 2022)	-

Affinivax got acquired by GSK on May 31, 2022.

Click here to take a look at Affinivax's acquisition in detail

Affinivax has raised a total funding of $359M over 5 rounds. Its first funding round was on Oct 30, 2014. Its latest funding round was a Series C round on Jan 07, 2021 for $*****. 13 investors participated in its latest round. Affinivax has 16 institutional investors.

Here is the list of recent funding rounds of Affinivax:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jan 07, 2021	6187135	Series C	2760950	9842991	2333221	5606350
Apr 23, 2020	7707800	Series B	8891992	1970529	3569878	Bain Capital & 1 more
Dec 22, 2017	9002875	Series A	8718002	2674018	4278729	4909174

Access funding benchmarks and valuations. Sign up today!

View details of Affinivax's funding rounds and investors

The founders of Affinivax is Steven Brugger.

Here are the details of Affinivax's key team members:

Steven Brugger: Founder of Affinivax.

View details of Affinivax's Founder profiles and Board Members

Affinivax's employee count trend

Affinivax has 132 employees as of Dec 22. The total employee count is 69.0% more than what it was in Dec 21. Here is Affinivax's employee count trend over the years:

Uncover Affinivax's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Affinivax include Insmed, Evofem and ImmunityBio. Here is the list of Top 10 competitors of Affinivax, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Insmed 1999, Bridgewater (United States), Public	Developer of small molecule inhibitors for rare lung diseases	-	Quaker Partners Management, Foresite Capital ... & 11 others	67/100
2nd	Evofem 2009, San Diego (United States), Public	Developer of sexual and reproductive health therapeutics	$100M	mercerstcap.com, Aditx Therapeutics & 10 others	66/100
3rd	ImmunityBio 2014, El Segundo (United States), Public	Developer of peptide-based vaccines for immunotherapy	$169M	Oberland Capital, Westlake Ventures & 1 others	66/100
4th	MaaT Pharma 2014, Lyon (France), Public	Developer of microbiome therapy for the treatment of intestinal dysbiosis diseases	$42.3M	Credit Mutuel Equity, Symbiosis & 11 others	65/100
5th	Osivax 2017, Lyon (France), Series B	Developer of vaccines against constantly mutating pathogens	$42.2M	EIC Fund, Noshaq & 10 others	63/100
6th	Brii Biosciences 2018, San Francisco (United States), Public	Developer of biologics to treat hepatitis B infection	$415M	Invesco, HongShan & 7 others	63/100
7th	SNIPR Biome 2011, Copenhagen (Denmark), Series B	Developer of CRISPR-based microbial gene therapy to target pathogenic bacteria precisely	$139M	Lundbeck Foundation, Life Sciences Partners ... & 7 others	63/100
8th	CStone Pharma 2016, Shanghai (China), Public	Developing and licensing novel drugs for diseases including cancer and autoimmune diseases	$410M	GIC, Boyu Capital & 14 others	59/100
9th	Affinivax 2013, Cambridge (United States), Acquired	Developer of technology-based conjugate vaccines against infectious diseases	$359M	Citadel, Logos & 14 others	59/100
10th	Centauri Therapeutics 2014, Kent (United Kingdom), Series A	Developer of immunotherapeutics to treat infectious diseases	$73M	Boehringer Ingelheim Venture Fund, REPAIR Impact Fund ... & 32 others	58/100